Product Description
Nifurtimox has been used to treat Chagas disease for 40 years, but tolerance and safety data in adults are scarce. Nifurtimox is poorly tolerated among adults with chronic Chagas disease, resulting in a low treatment completion rate. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/20932171/)
Mechanisms of Action: DNA Cleaver
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Chile | Colombia | Mexico | Peru | United Kingdom | United States
Approved Indications: Chagas Disease | Trypanosomiasis
Known Adverse Events: Abdominal Pain | Headache | Pain Unspecified
Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Brain Stem Cancer|Breast Cancer|Central Nervous System Cancer|Glioma|Lung Cancer|Medulloblastoma|Melanoma|Neuroblastoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CTR20190136 | P1 |
Recruiting |
Neuroblastoma |
None |
|
CTR20220156 | P1 |
Recruiting |
Brain Stem Cancer|Glioma|Central Nervous System Cancer|Lung Cancer|Medulloblastoma|Breast Cancer|Melanoma |
None |